MS Doesn't Just Attack Nerves — It Starves the Cells That Keep You Upright

Balance is one of those things the body does invisibly, a constant negotiation between the brain, the inner ear, the muscles, and a sprawling network of neurons that most people never think about until it starts to fail. For the roughly one million Americans living with multiple sclerosis, that failure is often slow, insidious, and deeply disorienting — not just physically, but psychologically. A new wave of research is beginning to explain why, and the answer reaches deeper than the nerve damage MS is famous for.

Scientists have long understood that MS is fundamentally an inflammatory disease, one in which the immune system turns against the myelin sheath that insulates nerve fibers. Strip away that insulation and signals slow down or stop entirely, producing the numbness, fatigue, and vision problems that define the condition. But a growing body of evidence suggests that inflammation is doing something else simultaneously, something that has received far less attention: it is quietly dismantling the energy infrastructure of the neurons responsible for movement and coordination.

The new research focuses on mitochondria, the organelles that generate the chemical fuel cells run on. In healthy neurons, mitochondria hum along reliably, supplying the energy that allows cells to fire, communicate, and survive. But in the inflamed environment of an MS-affected brain, that process breaks down. The mitochondria in movement-controlling neurons begin to malfunction, producing less energy and more cellular waste. Starved of fuel and increasingly toxic to themselves, these cells weaken. Over time, they die.

What makes this finding particularly significant is where it happens. The neurons most affected are those governing motor function and balance, the very systems that MS patients report losing first and most devastatingly. This is not random. Neurons that control movement tend to be large, metabolically demanding cells that require enormous and sustained energy output. They are, in a sense, the least forgiving targets for a mitochondrial crisis. When their power supply falters, the consequences show up immediately in the body — in the wobble of a gait, the reach that misses its mark, the fall that shouldn't have happened.

This reframes MS progression in an important way. The conventional picture of the disease emphasizes immune attacks on myelin as the primary driver of disability. That picture is accurate but incomplete. What this research adds is a parallel track of damage: an energy failure cascading through the motor system, independent of whether myelin is being actively stripped away at any given moment. It helps explain why some patients continue to deteriorate even when inflammation appears to be under control, a phenomenon that has frustrated neurologists and patients alike for decades.

The systems-level consequence here is worth sitting with. If mitochondrial dysfunction is driving neuronal death in MS independently of active immune flares, then treatments aimed solely at suppressing inflammation may be managing only half the problem. The disease-modifying therapies that have transformed MS care over the past two decades — drugs like natalizumab, ocrelizumab, and siponimod — are largely designed to reduce immune activity. They are genuinely effective, particularly in relapsing forms of the disease. But they were not designed to rescue failing mitochondria, and they may not be doing so.

This opens a door that researchers are only beginning to walk through. If the motor neuron death driving balance and coordination loss is partly a metabolic problem, then metabolic interventions become newly relevant. Compounds that support mitochondrial function, reduce oxidative stress, or improve cellular energy efficiency could theoretically slow the progression of motor symptoms even in patients whose inflammation is already being managed. Some researchers are already exploring this territory, looking at everything from repurposed diabetes drugs to targeted antioxidants as potential neuroprotective agents in MS.

The broader implication is a shift in how the field thinks about progressive MS, the form of the disease that tends to be most resistant to existing therapies. If neurodegeneration in MS is being driven not just by immune attacks but by a chronic energy deficit in vulnerable neurons, then slowing the disease may require treating it as both an inflammatory and a metabolic condition simultaneously. That is a more complex therapeutic target, but it may be a more honest one.

For patients, the significance is immediate and personal. Understanding that balance loss has a biological mechanism — one that can potentially be interrupted — is different from accepting it as an inevitable consequence of a disease that cannot be fully stopped. Science rarely moves as fast as patients need it to, but the direction here is meaningful. The neurons that keep people upright are not simply being attacked. They are being starved. And that, at least, is a problem someone might be able to feed.